Erytech
IPO
- Headquarters
- Lyon
- Employees
- 51–200
- Founded
- 2004
- Business Model
- B2B
- Website
- erytech.com
- Total Funding
- $274.6M
- Last Round
- $144.0M Private EquityNov 2017
About
ERYTECH is a clinical-stage biopharmaceutical company that developed innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Founded in Lyon, France in 2004, the company focused on encapsulating therapeutic agents inside red blood cells to reduce toxicity and improve efficacy. ERYTECH was listed on the Nasdaq Capital Market and Euronext Paris. The company later merged with PHERECYDES to form PHAXIAM Therapeutics, which subsequently entered judicial restructuring in 2025.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account